Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T helper type 17 (Th17) cell response induction refers to the process by which naive CD4+ T cells differentiate into Th17 cells, a distinct subset of pro-inflammatory T helper lymphocytes. Th17 cells are characterized primarily by their production of interleukin-17A (IL-17A), as well as other cytokines such as IL-17F, IL-21, and IL-22. The induction and function of Th17 cells play critical roles in host defense against extracellular pathogens—especially at mucosal and epithelial barriers—and are also implicated in the pathogenesis of various autoimmune and inflammatory diseases. The induction of a Th17 response involves antigen recognition by naive CD4+ T cells, followed by differentiation under specific cytokine conditions (TGFβ + IL-6 or IL-21 for initiation, IL-23 for maintenance). STAT3 signaling is central to this process.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T helper type 17 cell response induction.